The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

In this article, in addition to analyzing GSK's financial results for Q4 2024, I also presented an analysis of the most interesting developments in its portfolio. However, that's not all.

Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio The latest announcement is out from GlaxoSmithKline ( (GB:GSK)). GSK announced ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

UK drugmaker GSK is struggling to convince the market ... for GSK is to persuade investors it can rebuild its oncology portfolio, after leaving the market in 2015. It subsequently went back ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.